About: A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
source	Medline; PMC
abstract	Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here, we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. The fluorescence-based neutralization assay is specific to measure COVID-19 neutralizing antibodies without cross reacting with patient specimens with other viral, bacterial, or parasitic infections. Collectively, our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities.
has issue date	2020-08-13(xsd:dateTime)
bibo:doi	10.1038/s41467-020-17892-0
bibo:pmid	32792628
has license	cc-by
sha1sum (hex)	73fd66b276f278705a5d9c7c203dd060bb22d0b1
schema:url	https://doi.org/10.1038/s41467-020-17892-0
resource representing a document's title	A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
has PubMed Central identifier	PMC7426916
has PubMed identifier	32792628
schema:publication	Nat Commun
resource representing a document's body	covid:73fd66b276f278705a5d9c7c203dd060bb22d0b1#body_text
is schema:about of	named entity 'procedure' named entity 'SOP' named entity 'SARS-CoV-2' named entity '96-well plate' named entity 'EDTA' named entity 'PBS' named entity 'PBS' named entity 'serum' named entity 'Trypsin' named entity 'room temperature' named entity 'Cell Imaging' named entity 'serum' named entity 'PBS' named entity 'viruses' named entity 'serum' named entity 'staining' named entity 'Hoechst 33342' named entity 'infection rate' named entity 'infection rate' named entity 'growth medium' named entity 'inverted microscope' named entity '96-well plate' named entity 'infection' named entity 'BioTek' named entity 'trypsin inhibitor' named entity 'room temperature' named entity 'PBS' named entity 'DAPI' named entity 'BSL-3' named entity 'Centrifuge' named entity 'assay' named entity 'SARS-CoV-2' named entity 'Neutralization' named entity 'ASSAY' named entity 'OPERATION PROCEDURE' named entity 'NEUTRALIZATION' named entity 'STANDARD' named entity 'METHODS' named entity 'SARS-COV-2'
is part of of	Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here, we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. The fluorescence-based neutralization assay is specific to measure COVID-19 neutralizing antibodies without cross reacting with patient specimens with other viral, bacterial, or parasitic infections. Collectively, our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation covid:73fd66b276f278705a5d9c7c203dd060bb22d0b1#body_text

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software